MRK AI Stock Analysis – Buy, Hold, or Avoid?
Merck & Co., Inc. (MRK)
Merck (MRK) offers a compelling long-term investment case, with robust fundamentals, a strong product pipeline, and positive sentiment, despite near-term technical consolidation and moderate risk from patent expirations. The stock is fairly valued relative to peers, with upside potential from upcoming product launches and pipeline catalysts. Short-term volatility is possible, but the risk/reward profile is attractive for investors with a longer horizon.
Fundamentals
Merck & Co., Inc. (MRK) shows a fundamentally solid multi-year track record of revenue growth and consistent operating performance, driven by a diversified pharmaceutical portfolio. The most recent quarter saw a temporary net loss due to elevated R&D spend, but the company's revenue beat expectations, demonstrating continued underlying business strength. Despite a high P/E ratio and recent earnings volatility, MRK remains a leader in its sector with compelling long-term fundamentals.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
4.27% YoY
Q1 2026
Net Income
-183.48% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.3B | 16.3B | 17.2B | 15.8B | 15.6B | 15.6B | 16.7B | 16.1B |
| Revenue Growth YoY | +4.27% | +4.48% | +3.16% | -1.94% | -0.99% | +6.79% | +4.35% | +7.16% |
| Net Income | -4.2B | 3.0B | 5.8B | 4.4B | 5.1B | 3.7B | 3.2B | 5.5B |
| Net Income Growth YoY | -183.48% | -20.84% | +83.24% | -18.85% | +6.66% | +405.30% | -33.47% | +191.30% |
| EPS | -$1.72 | $1.20 | $2.32 | $1.76 | $2.01 | $1.48 | $1.25 | $2.15 |
| EPS Growth YoY | -185.57% | -18.92% | +85.60% | -18.14% | +6.91% | +408.33% | -33.16% | +191.49% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.92% | 70.49% | 75.59% | 75.65% | 75.13% | 75.50% | 75.51% | 76.76% |
| Operating Margin | -11.57% | 37.74% | 43.43% | 40.25% | 42.96% | 27.83% | 23.92% | 38.03% |
| Net Margin | -26.03% | 18.15% | 33.67% | 28.02% | 32.52% | 23.96% | 18.95% | 33.86% |
| Return on Equity (ROE) | -9.24% | 5.63% | 11.16% | 9.04% | 10.51% | 8.08% | 7.09% | 12.52% |
| Return on Assets (ROA) | -5.21% | 3.34% | 6.24% | 5.48% | 6.54% | 4.73% | 4.01% | 7.32% |
Technical Analysis
MRK is currently in a consolidative phase within a broader uptrend, indicated by a Stage 2 advancing phase and a golden cross (50 SMA above 200 SMA). While the RSI sits in a neutral zone around 41.6, momentum is moderate with the ADX suggesting a developing trend. Key resistance near $112 to $116 is being tested, with support levels around $107 and pivot points near $111 maintaining buying interest.
No extreme reading
Mixed signals
Trend developing
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Merck & Co., Inc. (MRK) shows a fundamentally solid multi-year track record of revenue growth and consistent operating performance, driven by a diversified pharmaceutical portfolio. The most recent quarter saw a temporary net loss due to elevated R&D spend, but the company's revenue beat expectations, demonstrating continued underlying business strength. Despite a high P/E ratio and recent earnings volatility, MRK remains a leader in its sector with compelling long-term fundamentals.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$-1.28
Estimated
$-1.47
Surprise
+$0.19
Surprise %
+12.93%
Revenue
Actual
$16.29B
Estimated
$15.85B
Surprise
+$439.67M
Surprise %
+2.77%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $-1.28 | $2.04 | $2.58 | $2.13 | $2.22 | $1.72 | $1.57 | $2.28 |
| EPS (Estimated) | $-1.47 | $2.01 | $2.36 | $2.03 | $2.13 | $1.85 | $1.50 | $2.15 |
| EPS Surprise | +$0.19 | +$0.03 | +$0.22 | +$0.10 | +$0.09 | -$0.13 | +$0.07 | +$0.13 |
| % Diff | +12.9% | +1.5% | +9.3% | +4.9% | +4.2% | -7.0% | +4.7% | +6.0% |
| Revenue | ||||||||
| Revenue (Actual) | $16.29B | $16.4B | $17.28B | $15.81B | $15.53B | $15.62B | $16.66B | $16.11B |
| Revenue (Estimated) | $15.85B | $16.2B | $16.98B | $15.86B | $15.34B | $15.48B | $16.47B | $15.87B |
| Revenue Surprise | +$439.67M | +$200.92M | +$297.85M | -$58.53M | +$190.13M | +$141.31M | +$183.35M | +$242.4M |
| % Diff | +2.8% | +1.2% | +1.8% | -0.4% | +1.2% | +0.9% | +1.1% | +1.5% |
Valuation
Merck (MRK) currently presents a valuation profile that is generally in line with healthcare sector peers, with mixed signals from recent quarterly earnings due to a transient loss but steady long-term growth prospects. Analyst consensus is positive, with a solid price target premium supported by robust fundamentals and promising product pipeline expansion. The valuation metrics suggest a fairly valued stock with near-term volatility risks balanced by long-term growth potential.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | -17.53 | 21.98 | 9.05 | 11.22 | 11.15 | 16.88 | 22.85 | 14.85 |
| Price to Sales | 18.26 | 15.96 | 12.19 | 12.58 | 14.50 | 16.18 | 17.32 | 20.12 |
| Price to Book | 6.48 | 4.95 | 4.04 | 4.06 | 4.69 | 5.46 | 6.48 | 7.44 |
| Enterprise Value to EBITDA | -181.08 | 34.37 | 27.25 | 30.49 | 32.36 | 48.78 | 55.67 | 47.07 |
| Enterprise Value to Revenue | 20.95 | 18.16 | 13.54 | 14.31 | 16.18 | 17.78 | 18.74 | 21.76 |
Sentiment & Analyst Ratings
Merck (MRK) is broadly viewed with positive sentiment driven by strong Q1 2026 earnings and solid product performance, particularly from KEYTRUDA and WINREVAIR. Analysts generally recommend Buy or Strong Buy, supported by raised earnings guidance and near-term pipeline catalysts, despite some concerns over acquisition charges and patent expiration risks.
Analyst Recommendations
Risk Assessment
Merck & Co. presents a mixed risk profile characterized by solid liquidity but increasing leverage. While the company maintains stable cash flow generation, key patent expirations in 2026 and beyond pose significant risks to revenue stability. Despite a strong market position in oncology and recent pipeline innovations, pricing pressures and competitive threats from generics and biosimilars present material challenges to growth sustainability.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q1 2026
Quick Ratio
Latest Quarter: Q1 2026
Debt-to-Equity
Latest Quarter: Q1 2026
Debt-to-Assets
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.30 | 1.54 | 1.66 | 1.42 | 1.41 | 1.36 | 1.36 | 1.47 |
| Quick Ratio | 1.06 | 1.30 | 1.44 | 1.17 | 1.16 | 1.15 | 1.15 | 1.22 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 1.07 | 0.96 | 0.80 | 0.72 | 0.72 | 0.83 | 0.86 | 0.87 |
| Debt-to-Assets | 0.38 | 0.37 | 0.32 | 0.30 | 0.30 | 0.33 | 0.32 | 0.34 |
Liquidity Assessment
Current Ratio: 1.30(Adequate)
Quick Ratio: 1.06(Strong)
The company has adequate liquidity but may face challenges in a downturn.
Solvency Assessment
Debt-to-Equity: 1.07(High)
Debt-to-Assets: 0.38(Moderate)
The company has relatively high debt levels, which may increase financial risk in economic downturns.
Frequently Asked Questions about MRK
AI Answers: Common Questions About MRK
Get AI-powered answers to the questions investors ask most about Merck & Co., Inc.
MRK is a good buy for medium- and long-term investors, trading at $111.38 with a P/E of 31.37 (temporarily elevated by R&D/acquisition charges) and price targets averaging $135. The stock is fairly valued relative to peers, with strong fundamentals and pipeline catalysts supporting future growth.
Unless your thesis has changed or you are a short-term trader reacting to technical resistance, there is no strong reason to sell. Fundamentals remain robust, sentiment is positive, and the recent earnings dip is due to strategic investment, not core weakness. Consider holding through near-term volatility.
The biggest risks are patent expirations on Keytruda (post-2028) and Januvia/Janumet (2026), which could cause steep revenue declines. Leverage is elevated (debt-to-equity >1.0, debt ~38% of assets), and regulatory/pricing pressures or pipeline setbacks could further impact margins and growth.
Analyst targets range from $100 to $150, averaging around $135. Technically, key resistance is $116-$120; a breakout above this could see upside toward $135. Downside support is $107, with risk to $104 if support fails.
MRK is fairly valued, with a P/E of 31.37 (temporarily high due to recent charges), price-to-sales and EV/EBITDA multiples in line with sector averages, and a price-to-book premium reflecting pipeline strength. The current valuation is justified by growth prospects and sector leadership.
MRK is fundamentally strong, with revenue up 4.2% YoY in Q1 2026, gross margins above 70%, and a resilient product portfolio. The recent net loss is due to R&D investment, not core weakness, and management expects margin normalization as new products launch.
Technically, MRK is consolidating below resistance ($112-$116) with a neutral RSI (41.6) and a bullish golden cross (50 SMA > 200 SMA). Short-term momentum is mixed, so traders should watch for a breakout above $116 or a pullback to $107-$111 for better entry.
Key catalysts include upcoming FDA decisions and product launches in oncology/immunology (mid-late 2026), integration of recent acquisitions, and continued strong performance from Keytruda and new pipeline assets. Earnings releases and regulatory milestones will be important to watch.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.